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Background: Transcription factors (TFs) and their binding sites (TFBSs) play a central role in the regulation of gene
expression. It is therefore vital to know how the allocation pattern of TFBSs affects the functioning of any particular
gene in vivo. A widely used method to analyze TFBSs in vivo is the chromatin immunoprecipitation (ChIP).
However, this method in its present state does not enable the individual investigation of densely arranged TFBSs
due to the underlying unspecific DNA fragmentation technique. This study describes a site-specific ChIP which
aggregates the benefits of both EMSA and in vivo footprinting in only one assay, thereby allowing the individual
detection and analysis of single binding motifs.
Findings: The standard ChIP protocol was modified by replacing the conventional DNA fragmentation, i. e. via
sonication or undirected enzymatic digestion (by MNase), through a sequence specific enzymatic digestion step.
This alteration enables the specific immunoprecipitation and individual examination of occupied sites, even in a
complex system of adjacent binding motifs in vivo. Immunoprecipitated chromatin was analyzed by PCR using two
primer sets - one for the specific detection of precipitated TFBSs and one for the validation of completeness of the
enzyme digestion step. The method was established exemplary for Sp1 TFBSs within the egfr promoter region.
Using this site-specific ChIP, we were able to confirm four previously described Sp1 binding sites within egfr
promoter region to be occupied by Sp1 in vivo. Despite the dense arrangement of the Sp1 TFBSs the improved
ChIP method was able to individually examine the allocation of all adjacent Sp1 TFBS at once. The broad
applicability of this site-specific ChIP could be demonstrated by analyzing these SP1 motifs in both osteosarcoma
cells and kidney carcinoma tissue.
Conclusions: The ChIP technology is a powerful tool for investigating transcription factors in vivo, especially in
cancer biology. The established site-specific enzyme digestion enables a reliable and individual detection option for
densely arranged binding motifs in vivo not provided by e.g. EMSA or in vivo footprinting. Given the important
function of transcription factors in neoplastic mechanism, our method enables a broad diversity of application
options for clinical studies.
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Transcription factors (TFs) are core elements of tran-
scriptional regulation and play also an important role in
the systems biology of cancer characterized by changes
in the expression levels of certain genes [1]. A complex
of more than 20 TFs molecules is involved in RNA
polymerase II initiation of transcription in the promoter
region for the majority of the genes [2]. The activity of
the transcription machinery is based on the arrangement
and the occupancy of transcription factor binding sites
(TFBSs) along the 5’-region of the gene. Because of this
dense arrangement and the necessity to analyze the indi-
vidual occupancy of the TFBSs to establish regulation
models, there is a strong demand for methods that
enable this type of individual analysis.
So far, several methods have been developed for iden-
tification and analysis of TFBSs. A commonly used
method to verify TFBSs is the electrophoretic mobility
shift assay (EMSA) [3]. Indeed, even though the gel
mobility shift analysis provides a fast and easy identifica-
tion of which nucleotides are required for TF binding, it
does not work under in vivo conditions [4]. On the
other hand, the method of in vivo footprinting [5]
enables the investigation of protein binding in living
cells, but this technique is only capable of identifying
DNA regions that are bound by protein, being not able
to identify which protein is responsible for the observed
footprint [4,6].
In contrast, the chromatin immunoprecipitation
(ChIP) offers a distinct advantage over EMSA and in
vivo footprinting, since the ChIP technique not only
specifies which nucleotides are bound, but also identifies
the interacting protein(s) in the context of in vivo sam-
ples [7]. In this context we use the term in vivo to refer
to any experiments performed on living cells weather
within or outside a whole organism (sometimes referred
to as ex vivo). Specific modifications of the ChIP assay
exist to enable the analysis of mammalian tissues,
thereby allowing the detection of differences in the
interaction of transcription factors and promoter regions
of genes in normal and neoplastic tissues [8,9]. How-
ever, the standard ChIP has its limitations. The applied
fragmentation techniques (sonication or enzymatic DNA
restriction by MNase digestion) are unspecific. The indi-
vidual analysis of neighboring TFBSs is therefore lim-
ited, since the standard ChIP technique does not
provide a DNA cleavage in specific positions flanking a
sole binding motif (see Figure 1). Approaches using
restriction enzyme digestion instead of the standard
methods to fragment chromatin in ChIP in order to
restrict analysis to particular gene regions or transcrip-
tion factor binding sites has been previously described
[10,11]. Nevertheless, the enzyme-based DNA
fragmentation used in these procedures is applied just
after immunoprecipitation or in combination with soni-
cation. Hence, these ChIP variations neither provide an
individual analysis of close neighboring TFBSs nor a dif-
ferentiation between occupied or non- occupied sites.
Accordingly, considering the currently available metho-
dology and the complexity of the Protein-DNA interac-
tion within transcriptional active gene regions, the
individual analysis of neighboring TFBSs is still a chal-
lenging task.
Thus, the aim of this study was to develop and opti-
mize a ChIP technique for the specific and individual
analysis of neighboring TFBSs at once in both cell cul-




In order to support the individual analysis of adjacent
TFBSs, we have developed an improved ChIP assay by
replacing the traditionally used random fragmentation
step with a site-specific enzyme digestion. This site-spe-
cific ChIP allows the immunoprecipitation and enrich-
ment of DNA fragments containing only one TFBS,
thus permitting to distinguish between adjacent occu-
pied and non- occupied binding sequences in vivo. The
principle of the site-specific ChIP and its advantages
over similar procedures like EMSA and in vivo foot-
printing is exemplified in Figure 1.
The site-specific ChIP was established in the challen-
ging sequence environment of the Epidermal Growth
Factor Receptor gene (egfr) focusing on the well
described transcription factor Sp1 (for experimental
d e s i g ns e eF i g u r e2 ) .T h eegfr contains a GC-rich pro-
moter region in which Sp1 has been previously
described to bind to four sites [12,13]. We reanalyzed
and verified these Sp1 binding sites using the TFBS pre-
diction program MatInspector V7.4.8 [14,15]. A listing
of the results obtained by the MatInspector analysis is
shown on Table 1. The binding motifs are located as
expected at closely neighboring positions between -471
and-88 bp upstream of the egfr translational start codon
(Table 1 and grey oval disks, Figure 2).
Three endonucleases were utilized for the site-specific
restriction: BfaI, RsaI and SacI. The immunoprecipitated
sequences were analyzed by PCR using two sets of pri-
mer assays (Table 2). The first set consisted of specific
primer assays targeting each binding site and was
designed to measure only the specific signal of occupied
TFBSs (grey bars, Figure 2). For verification purpose we
designed a second set of primer assays to control the
specific enzyme digestion by PCR. Each assay is span-
ning one enzyme cutting site (black bars, Figure 2). In
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Page 2 of 9Figure 1 Comparison of actual methods for TFBS analysis with the site-specific ChIP. Principles of commonly applied techniques for TFBS
analysis in comparison to the concept of the site-specific ChIP. (A) The Electrophoretic Mobility Shift Assay (EMSA) provides a specific
identification of nucleotides sequences involved in TF binding, but does not work under in vivo conditions. (B) The in vivo footprinting allows
the specification of which nucleotides are bound by TFs, but it is not capable to identify the protein(s) involved in binding. (C) Concept of the
site-specific ChIP in comparison to the standard ChIP method. By replacing the traditionally used random fragmentation step with a site-specific
enzyme digestion, this site-specific ChIP enables the immunoprecipitation and enrichment of single TFBSs, thus allowing a differentiation
between adjacent occupied and non- occupied binding sequences in vivo.
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Page 3 of 9the case of a successful enzyme digestion, these primer
combinations should not allow the detection of the tar-
geted sequence. The procedure was tested with the
EGFR expressing osteosarcoma cell line HOS and sam-
ples of kidney carcinoma tissue. For verification purpose,
the Sp1-directed site-specific ChIP was also tested on
the osteosarcoma cell lines MNNG, U2-OS and SJ-SA-1
(data not shown).
Analysis of the allocation of Sp1 binding sites in EGFR
expressing cells
The occupation of the four known Sp1 sites was clearly
confirmed in all analyzed osteosarcoma cell lines by
application of the site-specific ChIP, as shown in Figure
3 for the case of the HOS cell line. All Sp1 binding sites
targeting primer assays produced amplicons of the
expected lengths when DNA immunoprecipitated with
anti-Sp1 antibody was used as template (white arrows,
Figure 3A). Moreover, PCR analysis of the input control
and the anti-IgG ChIP-DNA was negative and con-
firmed the specificity of the site-specific ChIP (Figure
3A). The control using GAPDH primer resulted in
amplification of the targeted region only when the input
control was used as template, showing the accuracy of
the site-specific ChIP (Figure 3B). The control of the
Figure 2 Experimental design of the site-specific ChIP. Schematic illustration of the strategy used for the analysis of individual TFBSs (here
Sp1). Immunoprecipitation and isolation of occupied binding motifs was enabled by specific enzyme digestion on positions flanking the TFBSs.
Enzyme cutting sites of the respective endonucleases (RsaI, BfaI and SacI) are depicted by dashed lines. Immunoprecipitated DNA was analyzed
by PCR using two sets of primer assays; one for the specific detection of allocated Sp1 TFBSs and a control set for the determination of the
efficiency of the enzyme digestion. Sp1 TFBSs within egfr promoter region are represented by grey oval disks, indicating their positions in
relation to the translational start codon (ATG). Black bars depict the targeted egfr regions of the enzyme digestion control primer assays. Signals
appearing in the enzyme digestion control PCR indicate a failed fragmentation. The grey bars denote location and length of PCR products of
primers used for the specific detection of immunoprecipitated DNA fragments containing the targeted Sp1 binding sites (a, b, c, d). Signals
indicate binding sites with bound TF (here Sp1).
Table 1 Results of Sp1-TFBSs verification with MatInspector




start end capitals: core sequence
†
a -471 -457 1,0 0,942 gtgGGGCggcgcatg
b -303 -289 1,0 0,930 gcaGGGCgggaggag
c -224 -210 1,0 0,956 gggGGGCggaggctg
d -102 -88 0,772 0,883 gcgAGGCggggactc
‡ Numbering of the position is relative to the egfr translational start codon (ATG)
§ The maximum core similarity of 1.0 is only reached when the highest conserved bases of a matrix match exactly in the sequence [14,15]
$ A perfect match to the matrix gets a score of 1.00 (each sequence position corresponds to the highest conserved nucleotide at that position in the matrix), a
“good” match to the matrix usually has a similarity of > 0.80 [14,15]
† The “core sequence” of a matrix is defined as the (usually 4-5) highest conserved positions of the matrix [14,15]
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Page 4 of 9Table 2 Primer used for analysis of site-specific ChIP products
PCR approach Target Primer assay Sequence
Sp1 binding site a Sp1-a For: 5’-GCACAGATTTGGCTCGACCTGGA-3’
Rev: 5’-GAGCGGGTGCCCTGAGGAGTTAATT-3’
TFBS specific Sp1 binding site b Sp1-b For: 5’-TGGCCTTGGGTCCCCGCT-3’
Rev: 5’- AGGGCGGGAGGAGGAGGGAC-3
PCR Sp1 binding site c Sp1-c For: 5’-TAGACGTCCGGGCAGCCCCC-3’
Rev: 5’-TCGGGACTCCGGCCGCCT-3’
Sp1 binding site d Sp1-d For: 5’-AGACCGGACGACAGGCCACCT-3’
Rev: 5’-TCCCGATCAATACTGGACGGAGTCAG-3’
RsaI cutting site RsaI For: 5’-TGCCATTATCCGACGCTGGCTCTA-3’
Rev: 5’-GAGCGGGTGCCCTGAGGAGTTAATT-3’
BfaI cutting site BfaI For: 5’-GCACAGATTTGGCTCGACCTGGA-3’
Rev: 5’-AGGGCGGGAGGAGGAGGGAC-3’
enzyme digestion BfaI 2nd cutting site BfaI 2 For: 5’-TGGCCTTGGGTCCCCGCT-3’
Rev: 5’-CTTGGGTCCCCGCTGCTGGTT-3’
control BfaI 3rd cutting site BfaI 3 For: 5’-TAGACGTCCGGGCAGCCCCC-3’
Rev: 5’-GGTGGCCTGTCGTCCGGTCTG-3’
SacI cutting site SacI For: 5’-AGACCGGACGACAGGCCACCT-3’
Rev: 5’-CTTTTCCTCCAGAGCCCGACTCG-3’
ChIP control GAPDH unrelated region GAPDH For: 5’-GAGGAAGAGAGAGACCCTCACTG-3’
Rev: 5’-AGGGGTCTACATGGCAACTG-3’
Figure 3 Site-specific ChIP on cell culture extracts: Individual detection of Sp1 TFBSs within the egfr promoter region.P C R - b a s e d
analysis of DNA immunoprecipitated by site-specific ChIP targeting each Sp1 TFBSs within the egfr promoter region. Nuclei obtained from
formaldehyde-fixed Osteosarcoma HOS cells were lysed, and chromatin was fragmented by specific enzyme digestion. Chromatin was
immunoprecipitated either by normal rabbit IgG antibodies as a negative control or polyclonal Sp1 antiserum. Non-immunoprecipitated
chromatin was used as total input control. DNAs from either the input chromatin or immunoprecipitated chromatin were subjected to PCR
analysis using the Sp1 TFBSs targeting primers or restriction site flanking primers indicated in Figure 2. PCR of input DNA shows equivalent
starting material for the assay. As a negative control, primers amplifying a region within the 3’-UTR of the GAPDH gene were used. In the center
of the image, the egfr promoter region with all investigated Sp1 TFBSs and enzyme cleavage sites is shown. Dashed arrows point to the target
regions of the respective PCR assay. (A) Lanes 1-16 show PCR products of specific assays for bound TF (Sp1) a (Sp1-a), b (Sp1-b), c (Sp1-c) und d
(Sp1-d) (c.f. Figure 2 grey bars). White arrows depict the bound Sp1 binding sites. Templates order: PCR positive control (lymphocyte DNA), ChIP
input control DNA, DNA immunoprecipitated with anti-IgG (IP negative control), DNA immunoprecipitated with anti-Sp1. (B) Lanes 17-20 show
PCR products of the GAPDH control assay. (C) Lanes 21-35 show PCR products of primer assays for enzyme digestion control (c.f. Figure 2 black
bars). Templates order: uncleaved HOS DNA from whole cell lysate (uc-HOS: PCR positive control), DNA samples immunoprecipitated with anti-
IgG, DNA immunoprecipitated with anti-Sp1 antibody.
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Page 5 of 9enzymatic digestion using primers flanking enzyme cut-
ting positions showed no amplification of the targeted
sequence when DNA immunoprecipitated with anti-Sp1
antibody was used as template, proving that the DNA
was cleaved at the intended sites (Figure 3C). In con-
trast, the same reactions using uncleaved HOS DNA of
the same lysate as template produced the expected
amplicons encompassing the enzyme cutting position
(Figure 3C).
Application of Sp1-directed site-specific ChIP on EGFR
expressing tissue samples
The application of the modified site-specific ChIP for
tissue analysis on kidney carcinoma material revealed
comparable results to the experiments with cells,
thereby being equally successful (Figure 4). Interactions
of Sp1 with all four analyzed binding sites within the
egfr promoter could be individually detected using the
site-specific ChIP technique in combination with the
Sp1-TFBSs targeting PCR (Figure 4A). The enzyme
digestion control confirmed the specificity and precision
of the enzymatic fragmentation (Figure 4C).
Discussion
Even in the complex sequence environment of the egfr,
the site-specific ChIP proved to be an adequate and
effective method for the individual analysis of the TFBSs
in vivo. The site-specific ChIP provides an improvement
towards the standard ChIP method and further techni-
ques for TFBS analysis. It unites the benefits of both
EMSA and in vivo DNase I footprinting–the specific
detection and localization of neighboring occupied bind-
ing sites in vivo–in one assay. Hence, the usually per-
formed verification of the obtained results by a second
method is therefore unnecessary (Figure 1). In combina-
tion with the enzyme digestion control by PCR using
primers targeting regions spanning each enzyme cutting
site, the site-specific ChIP may be generally applied for
the investigation of any transcription factor recognition
site along the human genome.
Completeness in a molecular sense can only be
achieved by analysis methods which in situ detect all
possible realised combinations of truly existing binding
sites. No modern technology (including next generation
Figure 4 Verification of Sp1 TFBSs targeting site-specific ChIP on tissue extracts. Kidney carcinoma samples were chosen for adaptation of
the site-specific ChIP to tissue material. Tissue samples were formaldehyde-fixed and nuclei were isolated as described. Sp1 TFBSs and enzyme
cutting sites information, enzyme digestion, immunoprecipitation and PCR analysis are as described in the legend to Figure 3, with exception of
the uncleaved Kidney DNA from whole cell lysate (uc-Kidney, lanes 21, 24, 27, 30, 33). White arrows depict the bound Sp1 binding sites.
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reasonably approximates this completeness. Though, in
combination with a preceded consensus analysis using
an adequate algorithm (like MatInspector) our site-spe-
cific ChIP is an effective method for the selective identi-
fication of complex TFBSs structures.
For all restriction sites we used restriction enzymes
(BfaI, RsaI and SacI) which exhibit exactly the same
digestion and buffering conditions (incubation at 37°C
and 100% activity in the following restriction buffer: 20
mM Tris-acetate, 50 mM potassium acetate, 10 mM
Magnesium Acetate, 1 mM Dithiothreitol pH 7.9 at 25°
C). The concern that TFBSs might not be flanked by
naturally occurring restriction enzyme sites and not
separated by an appropriate distance from each other
seems, in accordance to our experience, to be a rare
event. At least in the case of the egfr, there were no
complications.
The suitability of the used anti-Sp1-Antibody for an
application in the ChIP-procedure has been checked
and assured by the supplier (Merck Millipore Co., Biller-
ica, MA). The utilized buffers are common to all anti-
body based ChIP assays.
By adjusting sample preparation and chromatin isola-
tion procedures the technique is also applicable on tis-
sue material, enabling a broad diversity of application
options for clinical and molecular studies.
The site-specific ChIP is not dedicated to high
throughput screening approaches but instead supports
the functional analysis of a complex regulation scheme
o fas i n g l eg e n ei nas y s t e m sb i o l o g yv i e w-i . g .t h e
interaction pattern between occupied TFBSs. The focus
of this work is develop a method for a) the detection of
new binding sites in combination with a preceded con-
sensus analysis and b) the individual examination of sin-
gle TFBSs allocation in a complex system of
neighboring binding motifs of the same type. Hence, the
site-specific ChIP technique does not provide an assess-
ment of whether the TF-binding is associated with gene
transcription, what is a common limitation of all ChIP-
variations. For answering the question of functional rele-
vance further methods have to be employed. E.g. site
directed mutagenesis or deletion analysis for TFBSs and
promoter activity investigation in vivo.S o ,t h em a i n
benefit of the site-specific ChIP lies in the investigation
of specific regulatory regions in greater detail.
Conclusions
The site-specific ChIP, which uses an endonuclease-
based TFBSs specific DNA fragmentation followed by a
PCR-based enzyme digestion control, opens new possi-
bilities for the functional investigation of complex neigh-
boring TFBSs systems of genes, even within GC-rich
regions. In combination with methods for TFBSs
prediction [16-18], chip-techniques and/or sequencing,
it is a specific and sensitive tool for the detailed charac-
terization of the activity of neighboring binding motifs
at once. The site-specific ChIP enables the individual
and reliable analysis of known and predicted binding
motifs in vivo, on both cultured cells and mammalian
tissue material. Hence, our method enables the detec-
tion of differences in the interaction of transcription fac-
tors and promoter regions of genes in normal and
neoplastic tissues, thereby opening new possibilities for
the investigation of the transcriptional regulation of
genes involved in cancer biology.
Methods
Site-specific Chromatin immunoprecipitation
For the cell line experiments we used 10
7 osteosarcoma
cells which were fixated by a 1% formaldehyde solu-
tion. The Nuclei were isolated using cell lysis buffer,
separated by centrifugation and resuspended in ade-
quate standard restriction buffer (New England Biolabs
I n c . ,I p s w i c h ,M A ) .C h r o m a t i nw a sf r a g m e n t e db ys u b -
jecting the nuclei to restriction enzyme digestion
according to Kang et al. [19], including the following
modifications. A simultaneous application of three
restriction endonucleases - BfaI, RsaI and SacI (New
England Biolabs Inc., Ipswich, MA) - was performed to
cleave the DNA at positions flanking each Sp1 binding
site within egfr intron 1. A complete DNA digestion
was achieved by chromatin treatment with 200 U of
each enzyme for 4 h at 37°C and further 100 U of each
enzyme for additional 16 h at 37°C. The nuclei were
then incubated with and 200 U aliquot of each enzyme
and 200 U of RNase for 2 h at 37°C. Completion of
restriction enzyme fragmentation was verified by elec-
trophoresis separation on a 1.5% agarose gel. The opti-
mization of the specific enzyme digestion based DNA
fragmentation is shown on Additional file 1: Figure S1.
Chromatin was isolated using nuclei lysis buffer. The
lysate was diluted 10-fold in ChIP dilution buffer and
equal aliquots of cleaved chromatin (equivalent to 2
million cells) from a single cell lysate were used for
immunoprecipitation with antibodies against Sp1 and
IgG (mock IP) as well as a control for the amount of
input DNA used in precipitations (input control). 3 μg
of the antibodies against Sp1 (Merck Millipore Co.,
Billerica, MA) and IgG (Sigma-Aldrich Co., St. Louis,
MO) were used. The antibody was captured with pro-
tein A/G agarose beads (Santa Cruz Biotechnology Inc.,
Santa Cruz, CA). After washing the beads-antibody-
chromatin complexes under stringent conditions,
reverse crosslinking and purification of ChIP DNA was
performed using Chelex-100 according to Nelson et al.
[20]. DNA from the non-antibody whole-cell control
supernatant was isolated as described in literature [20]
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steps not mentioned here were performed according to
established standards [20].
The tissues samples were processed as follows. 0.03 g
frozen kidney carcinoma tissue was chopped into small
pieces and thawed in freshly prepared PBS containing
1% formaldehyde for crosslinking. The tissue was homo-
genized to avoid cell clumps and the ChIP was per-
formed as described above for the cell culture
experiments.
PCR based detection of immunoprecipitated TFBSs
The detection of the immunoprecipitated Sp1 binding
sites was done by PCR. For each sample (DNA extracted
from either the input chromatin, the normal rabbit IgG
or the anti-Sp1-immunoprecipitated chromatin): 2.5 μl
ChIP-DNA template, 5 pmol of Sp1 binding site specific
p r i m e r ,1Uo fTaq DNA Polymerase, 1X PCR reaction
buffer II, 400 μM of each dNTP (Applied Biosystems)
and 1.3 mM MgCl2 were mixed for PCR amplification
in a 25 μl reaction volume. A defined amount of 4 ng
lymphocyte DNA was used for the internal control of
each PCR reaction approach. The PCR was started with
an initial denaturation of 95°C for 9 min, followed by a
secondary denaturation at 98°C for 1 min. Next 40
cycles of denaturation at 98°C for 10 sec, annealing at
65°C for 2 min, and a single product extension step at
72°C for 7 min followed. The PCR products were sepa-
rated on a 2% agarose gel and visualized by ethidium
bromide staining.
PCR based controls of site-specific ChIP
The control of completeness of the enzyme digestion
control was also performed by PCR as described and
carried out on DNA templates prepared from the Sp1
immunoprecipitated chromatin sample and the whole-
cell sample (input control), as well as uncleaved HOS
cells DNA from the same lysate (positive control).
For the negative control, primers spanning an unre-
lated genomic region within the 3’-UTR of the GAPDH
gene were used yielding a 97-bp product.
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